<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01476007</url>
  </required_header>
  <id_info>
    <org_study_id>2010-024129-20</org_study_id>
    <secondary_id>EC10-(115, 116, 117,119, 122)</secondary_id>
    <nct_id>NCT01476007</nct_id>
  </id_info>
  <brief_title>Oral/Intramuscular B12 to Treat Cobalamin Deficiency</brief_title>
  <acronym>OB12</acronym>
  <official_title>Oral Versus Intramuscular Cobalamin to Treat Cobalamin Deficiency: Noninferiority Randomised Controlled Trial Pragmatic and Multi-center in the Primary Healthcare Setting (OB12 Project)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gerencia de Atención Primaria, Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gerencia de Atención Primaria, Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine the effectiveness of oral versus intramuscular Cobalamin (vitamin
      B12) by restore cobalamin parameter in blood at 8, 26 and 52 weeks in ≥ 65 aged patients with
      Cobalamin Deficiency.

      Design: Noninferiority randomised controlled trial, pragmatic and multi-center in the primary
      healthcare setting (Madrid Region).

      Participants: ≥ 65 aged patients with Cobalamin Deficiency. Patients give inform consent.
      Number of patients: 320 (160 each arm). Assignment: randomized simple (automatic system).

      Variables. Main outcome variable: Cobalamin level standardization (yes/no). Secondary outcome
      variables: Adverse events. Adherence measurement of treatment. Health related quality of life
      questionnaire (Euroqol-5D). Satisfaction and preferences. Other variables: Gender. Age. Live
      alone. Vegetarian diet. Alcohols consume. Clinic Variables (symptoms and physical
      examination) and blood parameters. Drugs consume.

      Causes of all losses and withdrawals. Number of patients (age and gender) who declined to
      participate.

      All data (excluding patient identification data) will be record in an electronic database.

      Intervention group: oral Optovite® B12 1000 gammas. Control group: idem intramuscular.

      Analysis: Descriptive analysis (screening phase). Baseline comparison of the two intervention
      groups. Effect of cobalamin (main outcome variable). Security. Quality of life. Adherence
      measurement of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variables. Main outcome variable: Cobalamin level standardization (yes/no). Secondary outcome
      variables: Adverse events. Adherence measurement of treatment. Health related quality of life
      questionnaire (Euroqol-5D). Satisfaction and preferences. Other variables: Gender. Age. Live
      alone. Vegetarian diet. Alcohols consume. Clinic Variables (symptoms and physical
      examination) and blood parameters. Drugs consume.

      Causes of all losses and withdrawals. Number of patients (age and gender) who declined to
      participate.

      All data (excluding patient identification data) will be record in an electronic database.

      Intervention group: oral Optovite® B12 1000 gammas. Control group: idem intramuscular.

      Analysis: Descriptive analysis (screening phase). Baseline comparison of the two intervention
      groups. Effect of cobalamin (main outcome variable). Security. Quality of life. Adherence
      measurement of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">November 28, 2017</completion_date>
  <primary_completion_date type="Actual">November 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Cobalamin level standardization</measure>
    <time_frame>1 year</time_frame>
    <description>Change from Baseline in Cobalamin level at 52 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Vitamin B 12 Deficiency</condition>
  <arm_group>
    <arm_group_label>oral Cobalamin (vitamin B12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral Cobalamin (vitamin B12)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intramuscular Cobalamin (vitamin B12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intramuscular Cobalamin (vitamin B12)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral Cobalamin (vitamin B12)</intervention_name>
    <description>Intervention group: oral Optovite® B12 1000 gammas.</description>
    <arm_group_label>oral Cobalamin (vitamin B12)</arm_group_label>
    <other_name>Optovite®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intramuscular Cobalamin (vitamin B12)</intervention_name>
    <description>Control group: intramuscular Optovite® B12 1000 gammas.</description>
    <arm_group_label>intramuscular Cobalamin (vitamin B12)</arm_group_label>
    <other_name>Optovite® (intramuscular)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 65 aged patients with Cobalamin Deficiency.

          -  Patients give inform consent.

        Exclusion Criteria:

          -  Treatment with B12 (1 last year)

          -  Neurologic or psychiatric pathologies

          -  Folic acid &lt; 2.3ng/ml ...
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosario Riesgo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gerencia Atención Primaria. Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Sanz-Cuesta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gerencia Atención Primaria. Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel DelCura-González, MD Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gerencia Atención Primaria. Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesús Martín-Fernández, MD Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gerencia Atención Primaria. Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sofía Garrido-Elustondo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gerencia Atención Primaria. Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esperanza Escortell-Mayor, MD Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gerencia Atención Primaria. Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gerencia Atención Primaria, Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Sanz-Cuesta T, González-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-González I, Martín-Fernández J, Escortell-Mayor E, Rodríguez-Salvanés F, García-Solano M, González-González R, Martín-de la Sierra-San Agustín MÁ, Olmedo-Lucerón C, Sevillano Palmero ML, Mateo-Ruiz C, Medina-Bustillo B, Valdivia-Pérez A, García-de Blas-González F, Mariño-Suárez JE, Rodríguez-Barrientos R, Ariza-Cardiel G, Cabello-Ballesteros LM, Polentinos-Castro E, Rico-Blázquez M, Rodríguez-Monje MT, Soto-Díaz S, Martín-Iglesias S, Rodríguez-González R, Bretón-Lesmes I, Vicente-Herrero M, Sánchez-Díaz J, Gómez-Gascón T, Drake-Canela M, Asúnsolo-del Barco Á; OB12 Group. Oral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multicentre, non-inferiority clinical trial undertaken in the primary healthcare setting (Project OB12). BMC Public Health. 2012 May 31;12:394. doi: 10.1186/1471-2458-12-394.</citation>
    <PMID>22650964</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gerencia de Atención Primaria, Madrid</investigator_affiliation>
    <investigator_full_name>Esperanza Escortell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>primary health care</keyword>
  <keyword>Vitamin B 12 Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12 Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

